B-cell Malignancies
5
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
133%
Monoclonal Antibody
133%
Small Molecule
133%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
5 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
BeOne MedicinesZanubrutinib
AstraZenecaAZD5492
Eureka TherapeuticsLow dose ET019002- T Cells
Bristol Myers SquibbUrelumab
Gilead SciencesInfluenza Vaccine
Clinical Trials (5)
Total enrollment: 223 patients across 5 trials
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
Start: Jan 2020Est. completion: Dec 2028
Phase 3Active Not Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Start: Sep 2024Est. completion: Feb 2028174 patients
Phase 1/2Recruiting
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
Start: Aug 2018Est. completion: Sep 2020
Phase 1Unknown
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Start: Mar 2013Est. completion: Aug 201647 patients
Phase 1Completed
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Start: Oct 2018Est. completion: Oct 20192 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 223 patients
5 companies competing in this space